Apilimod dimesylate - LAM Therapeutics

Drug Profile

Apilimod dimesylate - LAM Therapeutics

Alternative Names: LAM 002A; LAM-002

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LAM Therapeutics
  • Class Antineoplastics; Antirheumatics; Hydrazines; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma
  • Preclinical Neurological disorders

Most Recent Events

  • 09 Dec 2017 Safety, efficacy, and pharmacokinetic data from a phase I trial in Non-Hodgkin's lymphoma presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-2017)
  • 30 Nov 2017 LAM Therapeutics enters into a collaboration with Genentech for atezolizumab to be used in combination with apilimod
  • 30 Nov 2017 Phase-II clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top